Skip to main content

Chemomab Therapeutics Ltd ADR(CMMB-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis

PR Newswire - Wed Jun 28, 2023

--Includes Extensive Data Showing that CM-101, Chemomab's CCL24-Neutralizing Antibody,ย  ย Interrupts the Fibro-Inflammatory Processes that Lead to PSC--

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe